Welcome message
NAFLD is beyond doubt one of the biggest challenges the hepatology community is facing worldwide, and its impact is ever growing. Yet, thanks to a huge effort from many stakeholders, the field is constantly moving ahead and substantial progress is made in our understanding of the disease and how we should manage it: from cell plates and organoids over animal models to people living with NAFLD, from natural history to prognostication, from prevention over diagnosis to treatment.
How to keep on speed with all that innovation? There is just one answer: join us at the EASL NAFLD Summit 2023!
The EASL NAFLD Summit 2023 will tackle the most recent innovations and insights in NAFLD, bridging fancy high tech research methodology with clinical implications, basic research insights with real patient’s experiences, complex issues of clinical trials with issues of disease awareness and changing policies.
Faithfull to EASL’s missions, we bring together young researchers and experienced seniors to debate on scientific issues, clinicians and KOLs to implement new knowledge in daily practice, a multidisciplinary group of healthcare providers across specialties to tackle a multisystem disease, and medical professionals and patients to understand the true needs of patients and to chance policies.
If you want to recharge your NAFLD research batteries, increase the quality level of your clinical NAFLD practice or simply fuel your knowledge with the most cutting edge information: explore the EASL NAFLD Summit 2023’s exciting program and join us in Prague for the globe’s leading scientific and educational NAFLD event!
The summit organisers,
Sven Francque, Jeffrey Lazarus, and Sophie Lotersztajn
EASL NAFLD Summit 2023 Organising Committee
Sven Francque
Belgium
Read the bio
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France. He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression and leading to his PhD in 2011. His research unit continues to study pathophysiological mechanisms of NASH. He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission. He participates in several clinical trials in the field is as scientific committee member or PI involved in several phase 2 and 3 trials in NAFLD. He is senior clinical researcher for the Research Fund of the Flemish government. He is currently chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and senior full professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp.
Jeffrey Lazarus
Spain
Read the bio
Prof Lazarus heads the health systems team at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona. He serves as Vice-Chair of the board of the EASL International Liver Foundation and is a member of the EASL Policy and Public Health Committee. He is also a steering committee member of the ACHIEVE European Hepatitis Elimination coalition and the Danish and Spanish viral hepatitis elimination coalitions. He is a PI on multiple viral hepatitis and NAFLD/NASH studies. He led the global NAFLD consensus statement and NAFLD models of care expert recommendation. He was part of the Lancet GastroHep Commission on Viral Hepatitis and led a working group on the EASL-Lancet European Liver Health Commission.
Sophie Lotersztajn
France
Read the bio
Sophie Lotersztajn, PhD, is Director of Research at the Institut National de la Santé et de la Recherche Médicale (INSERM). She is Deputy Director of the Center for Reasearch in Inflammation in Paris, and heads the group « inflammation and stress responses in chronic liver diseases », a fouding team of the laboratory of Excellence Inflamex. Her research focusses on the role of inflammation in chronic liver disease progression, with main interest on how macrophages and lymphocytes control liver fibrosis, injury and regeneration. She chaired and participated to several national and international evaluation committees (Fondation pour la Recherche Médicale, Inserm, EU etc..) and is a member of the american, european and french associations for the study of the liver. She has served as an Associate editor for American Journal of Physiology (2008-2018), for Journal of Hepatology (2015-2017) and as a co-Editor for Journal of Hepatology (2018-2019) . She is currently co-Editor of JHep Reports.
